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Background: Mechanisms involved in metabolic syndrome (MetS) development include insulin resistance, weight
regulation, inflammation and lipid metabolism. Aim of this study is to investigate the association of single
nucleotide polymorphisms (SNPs) involved in these mechanisms with MetS.
Methods: In a random sample of the EPIC-NL study (n = 1886), 38 SNPs associated with waist circumference,
insulin resistance, triglycerides, HDL cholesterol and inflammation in genome wide association studies (GWAS) were
selected from the 50K IBC array and one additional SNP was measured with KASPar chemistry. The five groups of
SNPs, each belonging to one of the metabolic endpoints mentioned above, were associated with MetS and
MetS-score using Goeman’s global test. For groups of SNPs significantly associated with the presence of MetS or
MetS-score, further analyses were conducted.
Results: The group of waist circumference SNPs was associated with waist circumference (P=0.03) and presence of
MetS (P=0.03). Furthermore, the group of SNPs related to insulin resistance was associated with MetS score (P<0.01),
HDL cholesterol (P<0.01), triglycerides (P<0.01) and HbA1C (P=0.04). Subsequent analyses showed that MC4R
rs17782312, involved in weight regulation, and IRS1 rs2943634, related to insulin resistance were associated with
MetS (OR 1.16, 95%CI 1.02-1.32 and OR 0.88, 95% CI 0.79; 0.97, respectively). The groups of inflammation and lipid
SNPs were neither associated with presence of MetS nor with MetS score.
Conclusions: In this study we found support for the hypothesis that weight regulation and insulin metabolism are
involved in MetS development. MC4R rs17782312 and IRS1 rs2943634 may explain part of the genetic variation in
MetS.
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The metabolic syndrome (MetS) is a common multi-
component condition consisting of abdominal obesity,
dyslipidaemia, hypertension and hyperglycaemia. It is
associated with an increased risk of CVD (cardiovascular
diseases) and T2D(type 2 diabetes) [1]. A central* Correspondence: cecile.povel@wur.nl
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reproduction in any medium, provided the orquestion in understanding MetS is why its underlying
traits cluster together.
Several mechanisms, including insulin resistance [1],
abdominal obesity [1], and inflammation [2,3] have been
proposed to underlie the clustering of MetS features.
However, the etiology of MetS has not been unravelled
completely yet. Genetic association studies may help to
better understand MetS etiology.
A systematic review of genetic association studies on
MetS showed that until now most SNPs for which an as-
sociation with MetS has been found were involved intd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ation study (GWAS) even all single nucleotide poly-
morphisms (SNPs) associated with MetS were involved
in lipid metabolism [5]. If effect sizes of SNPs involved
in weight regulation and insulin resistance, pathways for
which strong pathophysiological evidence exists [1], are
small, these SNPs would not have been detected in
GWAS, which have a low power due to adjustment for
the large number of associations tested.
The SNPs for which an association with MetS has
been established explain only a small part of the genetic
variation in MetS [4-6]. Therefore, many more genetic
variants remain to be discovered. SNPs associated with
insulin resistance, abdominal obesity, inflammation and
lipid levels in GWAS are likely candidates for an associ-
ation with MetS itself. For several of these SNPs, how-
ever, an association with MetS has not been investigated
with a candidate gene approach.
A common feature of genetic association studies is
that the power to detect associations is low, because of
small effect sizes and the small alpha caused by adjust-
ment for multiple testing. A way to account for this
problem is to increase the effect size and reduce the
number of tests, by studying the joint effect of a group
of SNPs [7]. To the best of our knowledge such an
approach has not been undertaken in relation to MetS.
Therefore the aim of this study is to get more insight
in the etiology of MetS, by studying associations
between MetS and groups of SNPs that were found to
be related to insulin resistance, abdominal obesity,
inflammation or lipid levels in GWAS. For those groups
of SNPs associated with MetS, we also study the associ-
ation with the individual SNPs in this group.
Methods
EPIC-NL: Study design
In the EPIC-NL cohort the two Dutch contributions to
the European Investigation into Cancer and Nutrition
(EPIC) project are combined: the Prospect-EPIC and the
MORGEN-EPIC (Monitoring Project on Risk Factors for
Chronic Diseases) cohorts. Both cohorts were initiated
in 1993.The study design of the combined cohort is
described in detail elsewhere [8]. In brief, Prospect is a
prospective cohort study among 17 357 women aged
49–70 who participated in a breast cancer screening
program between 1993 and 1997. The MORGEN-
project consists of 22 654 men and women aged 20–59
years recruited from three Dutch towns (Amsterdam,
Doetinchem, and Maastricht). From 1993 to 1997, each
year a new random sample of approximately 5000 indivi-
duals were examined.
Laboratory and genetic analyses were performed in a
6.5% random sample of the EPIC-NL study, in all inci-
dent T2D cases and in all incident CVD cases. In ourstudy we only used the random sample. After exclusion
of participants with missing blood samples (n = 157),
missing values for haemoglobin A1c (HbA1C), waist cir-
cumference, high-density lipoprotein (HDL) cholesterol,
systolic blood pressure, diastolic blood pressure, trigly-
cerides or C-reactive protein (CRP) (n = 128), or with
missing SNP data (n=433) the study population con-
sisted of 1886 participants. All participants signed
informed consent before study inclusion. Both stud-
ies complied with the Declaration of Helsinki. The
Prospect-EPIC study was approved by the Institutional
Review Board of the University Medical Center Utrecht
and the MORGEN project was approved by the Medical
Ethical Committee of TNO, The Netherlands.
Baseline measurements
At baseline, a physical examination was performed and
non-fasting blood samples were drawn. During the phys-
ical examination, systolic and diastolic blood pressure
measurements were performed twice in the supine pos-
ition on the right arm using a BosoOscillomat (Bosch &
Son, Jungingen, Germany) (Prospect) or on the left arm
using a random zero sphygmomanometer (MORGEN).
The mean of both measurements was taken. Waist cir-
cumference and height were measured to the nearest 0.5
cm. Body weight was measured with light indoor cloth-
ing without shoes on, to the nearest 100 gr.
Biomarker measurements
HbA1c was measured with a homogeneous assay with
enzymatic endpoint in erythrocytes. Trigycerides were
measured in EDTA plasma using enzymatic methods,
whereas hsCRP was measured with a turbidimetric
method [8]. MetS was defined according to an adapted
version of the AHA/NHLBI MetS definition as having at
least 3 of the following 5 MetS features [9]: abdominal
obesity (waist circumference ♂≥102 cm; ♀≥ 88 cm); low
HDL cholesterol (♂ <1.0; ♀<1.3 mmol/L); hypertrigly-
ceridemia ( ≥1.7 mmol/L); hypertension ( ≥130/85 mm
Hg or use of hypertensive medicication); hyperglycemia
(HbA1C ≥5.7% or glucose lowering medication) [10,11].
MetS-score was calculated by summing the number of
MetS features present in each participant.
Genotyping
Genomic DNA was extracted in different batches using
standard methods, such as salting out, QIAampW Blood
Kit (Qiagen Inc., Valencia, CA, USA). The participants
were genotyped using a gene-centric 50K iSelect chip
array, further referred to as IBC array [12]. The design
and coverage of the IBC array compared to conventional
genome-wide genotyping arrays has been described
in detail elsewhere [12]. Additionally, the MC4R
rs17782313SNP was genotyped in 853 women of the
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specific PCR SNP genotyping that uses FRET quencher
cassette oligos [13]. For this SNP genomic DNA was
extracted with an in-house developed extraction method
at Kbiosciences (Hoddesdon Herts, UK).
From the available SNPs, we selected those signifi-
cantly associated (P≤1.0*10-5) with waist circumference,
inflammatory markers, triglycerides or HDL cholesterol
or homeostasis model assessment insulin resistance
(HOMA-IR) in published GWAS until 01-01-2011. As
only a few GWAS on HOMA-IR are conducted, we add-
itionally included SNPs both associated with a glucose
related traits in GWAS (P≤1.0*10-5) and with HOMA-IR
(P≤0.05). Highly correlated proxy SNPs were included in
case the original SNP from the GWAS was not available
on the IBC array (r2CEU 1000 Genome Pilot 1 ≥ 0.80). If SNPs
were only found in one GWAS, without a replication sam-
ple, they were excluded. In total we included 39 SNPs: 2
SNPs associated with waist circumference, 5 SNPs asso-
ciated with insulin resistance, 6 SNPs associated with in-
flammation, 16 SNPs associated with triglycerides and 16
SNPs associated with HDL cholesterol (Table 1). Sixteen
SNPs which were associated in GWAS with waist circum-
ference, inflammatory biomarkers and lipid levels were
not on the IBC CVD array (Appendix I).
Statistics
Distributions of genotypes were tested for deviation
from hardy-weinberg equilibrium (HWE) by chi-square
analyses. Triglycerides and hsCRP were log-transformed
to improve normality. Participants on blood pressure
medication were excluded from the analyses on blood
pressure, participants on glucose lowering medication
from the analysis on HbA1C, and participants with acute
inflammation (hsCRP > 10 mmol/L) from the analyses
on hsCRP.
SNPs were divided into 5 groups (Table 1) according
to the known associations in GWAS. These groups of
SNPs were associated with the corresponding phenotype
using the linear regression model of Goeman’s global
test [7]. Subsequently, for each group of SNPs the asso-
ciation with MetS was analysed using the log-linear
model of Goeman’s global test, and the association with
MetS-score using the linear regression model of
Goeman’s global test (see Figure 1: data-analyses
scheme). If one of these associations was statistically sig-
nificant, we conducted additional data-analyses. First, to
see whether the association with the group of SNPs was
mediated by the corresponding phenotype from GWAS,
we adjusted the association between MetS and the group
of SNPs for this phenotype. Second, we tested if the
group of SNPs was also associated with the individual
MetS features or hsCRP using the linear regression
model of Goeman’s global test. Third, we analysed theassociation of the individual SNPs in this group with
MetS using log-linear models and with MetS-score using
linear regression. For the individual SNPs which were
significantly associated with MetS or MetS-score, we
analysed associations with the individual MetS features
and hsCRP using linear regression. We only conducted
analyses with individual SNPs, for those SNPs which
were on the group level associated with MetS or MetS-
score. Consequently, only a few associations with indi-
vidual SNPs were analyses. Therefore, adjustment for
multiple testing is not appropriate.
All analyses were adjusted for age, sex and cohort. Sig-
nificance was defined as a 2-sided P-value <0.05. The
global test was calculated in R version 2.12.1 (R Founda-
tion for Statistical Computing; www.r-project.org). The
analyses for individual SNPs were performed with SAS
version 9.2 (SAS Institute, INC., Cary, North Carolina).
Results
All SNPs were in HWE (P>0.05). Minor allele frequency
of the SNPs ranged from 0.04-0.47 (Table 1). The ran-
dom sample of EPIC-NL consisted of 465 men and 1421
women (Table 2). The mean age was 50.1 (SD 11.7) and
30.3% of all participants had MetS.
The group of abdominal obesity SNPs was significantly
associated with waist circumference (P=0.01), the group
of insulin resistance SNP with HbA1C (P=0.04) and the
group of inflammation SNPs with hsCRP (P=7.3*10-6).
In contrast, the group of triglyceride SNPs was not sig-
nificantly associated with serum triglycerides (p=0.08)
and the group of HDL cholesterol SNPs not with HDL
cholesterol (P=0.32).
P-values for the association of all groups of SNPs with
MetS or MetS-score are shown in Table 3. The group of
SNPs known for their association with insulin resistance,
was borderline significantly associated with MetS
(P=0.06) and statistical significantly associated with
MetS-score (P=0.003). This group of SNPs was also sig-
nificantly associated with HbA1C, triglycerides and HDL
cholesterol (Table 3). The associations of this group of
SNPs with MetS-score and MetS features weakened
slightly after adjustment for HbA1C (Table 3). Of the
five insulin resistance SNPs included in the group IRS1
rs2943634 was the only SNP individually associated with
MetS or MetS-score (Table 4). These associations
remained after adjustment for HbA1C (data not shown).
IRS1 rs2943634 was also associated with HbA1C (per al-
lele difference −0.034, 95% CI −0.070; 0.002), triglycer-
ides (per allele difference −0.051, 95% CI −0.085; -0.017)
and HDL cholesterol (per allele difference 0.029, 95% CI
0.008; 0.052).
The group of SNPs known for their association with
waist circumference, was statistical significantly associated
with MetS (P=0.03) and tended to be associated with
Table 1 SNPs included in the analyses of random sample of EPIC-NL (n=1886)
Gene SNP (literature) SNP (dataset) MAF (dataset) ref r2 SNPs
Insulin resistance
PPARG rs1801282 rs1801282 G: 0.13 [14] -
IRS1 rs2943634 rs2943634 A: 0.35 [15] -
GCKR rs780094 rs780094 T: 0.37 [14] -
IGF1 rs35767 rs35767 A: 0.16 [14] -
GCK rs4607517 rs1799884 T: 0.18 [14] 1
Abdominal obesity
FTO rs1421085 rs1421085 C: 0.40 [16] -
MC4R1 rs17782313 rs17782313 C: 0.25 [16] -
Inflammation
IL6R rs4537545 rs4537545 T: 0.39 [17] -
LEPR rs6700896 rs1805096 A: 0.38 [17] 0.89
CRP rs7553007 rs1341665 A: 0.32 [17] 1
ADIPOQ rs1648707 rs182052 A: 0.34 [18] 1
IL18 rs1834481 rs5744256 G: 0.26 [19] 1
GCKR rs780094 rs780094 T: 0.37 [20] -
Triglycerides
AFF1 rs442177 rs3775214 G: 0.43 [21] 0.96
APOB rs673548 rs673548 A: 0.22 [22] -
APOB rs693 rs693 G: 0.50 [23] -
APOA5-A4-C3-A1 rs12286037 rs12286037 T: 0.08 [24] -
APOA5 rs6589566 rs2075290 C: 0.06 [25] 1
FADS1 rs174548 rs174548 G: 0.29 [21]
FADS1-2-3 rs174547 rs174577 A: 0.35 [26] 1
GALNT2 rs4846914 rs4846914 G: 0.41 [23] -
LPL rs328 rs328 G: 0.10 [23] -
MLXIPL rs17145738 rs17145750 T: 0.16 [24] 0.86
PLTP rs7679 rs6073952 A: 0.20 [26] 0.82
TRIB1 rs2954029 rs2954029 T: 0.47 [26] -
CLIP2 rs16996148 rs16996148 T: 0.10 [24] -
GCKR rs780094 rs780094 T: 0.37 [27] -
ANGPTL3-DOCK7 rs1748195 rs1748197 A: 0.35 [24] 1
ANGPTL3-DOCK7 rs12130333 rs12130333 T: 0.24 [23] -
HDL cholesterol
ABCA1 rs1883025 rs1883025 T: 0.24 [26] -
ABCA1 rs3890182 rs3890182 A: 0.10 [21] -
APOB rs11902417 rs11902417 A: 0.24 [21] -
CETP rs1800775 rs1800775 A: 0.46 [28] -
CETP rs3764261 rs3764261 A: 0.31 [29] -
FADS1 rs174548 rs174548 G: 0.29 [21] -
FADS1-2-3 rs174547 rs174577 A: 0.35 [26] -
GALNT2 rs4846914 rs4846914 G: 0.41 [23] -
LCAT rs255052 rs255052 A: 0.17 [24] -
LCAT rs12449157 rs1109166 C: 0.18 [21] 0.94
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Table 1 SNPs included in the analyses of random sample of EPIC-NL (n=1886) (Continued)
LIPC rs1800588 rs1800588 T: 0.22 [23] -
LIPG rs2156552 rs2156552 A: 0.16 [21] -
LPL rs328 rs328 G: 0.10 [23] -
PLTP rs7679 rs6073952 A: 0.20 [26] 0.82
MMAB MVK rs2338104 rs10774708 A: 0.47 [26] 1
HNF4A rs1800961 rs1800961 T: 0.04 [26] -
1Data available in 853 women.
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suggested association with MetS-score disappeared after
adjustment for waist circumference (Table 3). Further-
more, no association was found with any individual MetS
feature except for waist circumference (Table 3). Of the
two abdominal obesity SNPs only MC4R rs17782313 was
individually associated with MetS (Table 4). This associ-
ation remained after adjustment for waist circumference.
MC4R rs17782313 was not associated with any indi-
vidual MetS feature, including waist circumference itself
(data not shown). The groups of SNPs linked in GWAS
with inflammation, triglycerides or HDL cholesterol
were neither associated with MetS nor with MetS-score
(all P-values ≥ 0.15). Therefore no further data-analyses
were done for these groups of SNPs.Discussion
In this population based study of 1886 participants, we
studied the relation between MetS and groups of SNPs
associated in GWAS with waist circumference, insulin
resistance, inflammation, triglycerides or HDL choles-
terol. Only the group of waist circumference SNPs and
the group of insulin resistance SNPs were associated
with MetS or MetS-score.Figure 1 Flow diagram of analyses.Waist circumference SNPs
In our study the group of SNPs which were associated
with waist circumference in GWAS (MC4R rs17782313
and FTO rs1421085) was associated with waist circum-
ference, as well as with MetS. The association with MetS
disappeared after adjustment for waist circumference,
indicating that the association with MetS is driven by
the association with waist circumference. Furthermore,
the association with MetS seemed mainly to be driven
by MC4R rs17782313. In the KORA study among 7888
adults, an association between MC4R rs2229616 (r2=1
with rs17782313) and MetS was found [30], supporting
our findings. Unfortunately, in our study, data on MC4R
rs17782313 were available for women only. However,
since in the KORA study [30] the association between
MC4R rs2229616 and MetS was not dependent on sex,
we expect that this did not influence our findings. In our
study the association between MC4R rs17782313 and
MetS remained after adjustment for waist circumference.
Furthermore, we found no association between MC4R
rs17782313 and any individual MetS feature, including
waist circumference. This suggests that the association
between MC4R rs17782313 and MetS, is at least in part,
independent of body weight. In both human and animal
studies MC4R rs17782313 had an effect on insulin
Table 2 Characteristics of the random sample of EPIC-NL
(n=1886)
Total
(n=1886)
Men
(n=465)
Women
(n=1421)
Sex (% men) 24.6 (465)
Age (yr) 50.1 (11.7) 43.9 (11.1) 52.2 (11.2)
Waist circumference (cm) 85.5 (11.6) 92.0 (11.4) 82.9 (10.5)
Abdominal obesity(%)a 27.7(522) 21.9 (102) 29.6 (420)
HbA1C (%) 5.46 (0.69) 5.27 (0.61) 5.53 (0.71)
Hyperglycemiaa 28.3 (534) 17.8 (83) 31.7 (451)
Diabetic medication(%) 1.2 (22) 0.2 (1) 1.5 (21)
HDL-cholesterol (mmol/L) 1.27 (0.35) 1.14 (0.28) 1.31 (0.36)
Low HDL-cholesterol(%)a 47.8 (902) 29.2 (136) 53.9 (766)
Triglyceride (mmol/L) b, c 1.32
(0.91-1.98)
1.72
(1.15-2.40)
1.22
(0.85-1.80)
Hypertriglyceridemia a, b 33.8 (637) 50.8 (236) 28.2 (401)
Systolic blood pressure (mm Hg) 126.9 (18.5) 127.1 (14.8) 126.8 (19.5)
Diastolic blood pressure (mm Hg) 78.2 (10.4) 80.3 (10.1) 77.5 (10.4)
Hypertension(%)a 45.6 (860) 47.1(219) 45.1 (641)
Blood pressure lowering
medication (%)
10.7 (202) 5.6 (26) 12.4 (176)
High sensitive CRP (mmol/L) 1.41
(0.62-3.39)
1.20
(0.53-2.82)
1.49
(0.66-3.70)
MetS-score (number of features) 1.8 (1.4) 1.7 (1.3) 1.9 (1.4)
MetS prevalence(%)a 30.3 (572) 25.2 (117) 32.0 (455)
Data are presented as means (standard deviation), median with inter-quartile
range or % (n); HbA1C haemoglobin A1c, MetS metabolic syndrome, hsCRP
high sensitive C-reactive protein.
aAbdominal obesity, low HDL cholesterol, hypertension, hypertriglyceridemia
and MetS are defined according to the criteria of AHA-NHLBI (2005).
Hyperglycemia is defined according to the criteria of the American Diabetes
Association (2010). Abdominal obesity: ♂ ≥102 cm; ♀≥ 88 cm; Low HDL:
♂ <1.0; ♀<1.3 mmol/L; Hypertriglyceridemia: ≥1.7 mmol/L; Hypertension: ≥130/
85 mm Hg or use of hypertensive medication; Hyperglycemia: HbA1C in National
Glycohemoglobin Standarization Program (NGSP) units ≥ 5.7% or glucose
lowering medication; MetS is defined as having at least 3 MetS features.
bNon-fasting values.
cNo information on lipid lowering medication is available.
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fore, insulin resistance may explain part of the associ-
ation between MC4R rs17782313 and MetS. Contrary to
a meta-analysis among 12,555 Europeans, in which FTO
rs9939609 (r2=1 with rs1421085) was significantly asso-
ciated with MetS (OR 1.17 ; 95% CI 1.10-1.25) [33], we
did not observe an association between FTO rs1421085
and MetS. This discrepancy may be explained by the
weak association between FTO rs1421085 and waist
circumference in our study. In our study the regression
coefficient between FTO rs1421085 and waist circumfer-
ence was 0.03 per SD, whereas in other studies it ranged
from 0.07 per SD to 0.14 per SD [33].Insulin resistance SNPs
We found an association between insulin resistance
SNPs and MetS and MetS-score that remained afteradjustment for HbA1c, indicating that this association
was not driven by HbA1C. However, since HbA1C is not
an optimal marker of insulin resistance (r2 between
HOMA-IR – HbA1C ≈0.50 [34]), we can not rule out
that insulin resistance mediates this association. Out of
the group of five insulin resistance SNPs, IRS1
rs2943634 was the only SNP significantly associated with
MetS and MetS score. It was also associated with
HbA1C, triglycerides and HDL cholesterol. Accordingly
an IRS1 knock-out mouse model displayed a MetS like
phenotype with insulin resistance, increased blood pres-
sure, increased triglycerides, decreased HDL cholesterol
and decreased LPL activity [35]. Furthermore, in human
studies IRS1 rs2943634 has been associate with glucose
related [15] and lipid traits [36]. In contrast, in a study
among 1126 non-Hispanic whites, 898 non-Hispanic
blacks and 906 Mexican Americans, IRS1 rs7578326
(r2 with rs2943634=0.82) was not associated with MetS,
neither in the overall population, nor in specific ethnic
groups [37]. However, as the number of Caucasian parti-
cipants and MetS prevalence were lower than in our
study, the former study may have been underpowered in
Caucasian. Besides IRS1 rs2943634 the group of insulin
resistance SNPs consisted of PPARG rs1801282, GCKR
rs780094, GCKrs1799884, and IGF1rs35767. In line with
other studies, none of these SNPs were associated with
MetS in our data [4,37,38]. This may be explained by the
relatively weak effect on HOMA-IR of PPARG
rs1801282, GCK rs1799884, and IGF1 rs35767 [14,15] or
by pleiotropic effects of PPARG rs1801282 and GCKR
rs780094. The 12Pro allele of PPARG rs1801282 has
opposite effects on insulin resistance and BMI in Cauca-
sian subjects [39,40], whereas GCKR rs780094 has oppo-
site effects on insulin resistance and lipid levels [27].
These opposite effects may result in a zero association
with MetS, as observed by for example Passaro et al. [40].
Lipid SNPs
We did not observe an association between groups of
SNPs known for their association with triglycerides or
HDL cholesterol and MetS. On the contrary, in a GWAS
[5] and a systematic review of genetic association studies
[4], the majority of SNPs associated with MetS was
involved in lipid metabolism. The lack of an association
with MetS may be a power issue, because the association
between lipid SNPs and lipid levels was relatively weak
in EPIC-NL. Subgroup analyses revealed that these weak
associations were consistent for all lipid SNPs and could
not be explained by medication use, sex or a difference
between the MORGEN and Prospect study. Further-
more, it is unlikely that the non-fasting state of our sam-
ples gives an explanation, as in a GWAS, the association
with lipid levels was independent of the fasting state for
most SNPs [41].
Table 3 P-values for Goeman’s global test, testing the statistical significance of associations of waist circumference and
insulin resistance SNPs with metabolic syndrome and related features
Group
of SNPs
MetS MetS-score WC (cm) HbA1C (%) Log (TG)
(mmol/L)
HDL
(mmol/L)
SBP
(mm HG)
DBP
(mm HG)
Log (CRP)
(mmol/L)
n 1886 1886 1886 18641 1886 1886 16843 16843 16832
WC4 P=0.03 P=0.08 P=0.01 P=0.73 P=0.81 P=0.36 P=0.29 P=0.11 P=0.22
Adj WC P=0.16 P=0.80 - P=0.47 P=0.55 P=0.09 P=0.36 P=0.34 P=0.68
IR P=0.06 P=0.003 P=0.45 P=0.04 P=0.0003 P=0.0005 P=0.07 P=0.16 P=0.16
Adj HbA1C P=0.12 P=0.01 P=0.70 - P=0.0005 P=0.0008 P=0.10 P=0.22 P=0.17
All analyses are adjusted for age, sex and cohort; Mets Metabolic syndrome, WC waist circumference, TG triglycerides, HDL HDL-cholesterol, HbA1C haemoglobin
A1c, SBP systolic blood pressure, DBP diastolic blood pressure, Adj, adjusted, IR insulin resistance.
1Subjects which are using glucose lowering medication are excluded.
2Subjects with CRP > 10 mmol/L are excluded.
3Subjects with blood pressure lowering medication are excluded.
4Data available in 853 women.
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We found no significant association between a group of
inflammation SNPs and MetS. Accordingly, in a study
among 4286 British women, a CRP haplotype was not
associated with the individual features of MetS [42]. Fur-
thermore, Rafiq et al. could not detect an association
between T2D, an endpoint of MetS and 8 SNPs known
to alter circulating levels of inflammatory proteins,
which were located in the IL-18, IL1RN, IL6R, MIF, PAII
and CRP genes [43]. Overall, this evidence may suggest
that genetic variants in inflammatory genes do not play
a causal role in MetS development. However, for several
reasons it cannot be ruled out that some SNPs in inflam-
matory pathways are causally related to MetS. First, for
some inflammatory proteins SNP-MetS associations
have not been investigated yet. Second, as the global test
gives a combined result for all SNPs, the global test may
be not significant despite the presence of an association
between one of the single SNPs and MetS.Table 4 Individual SNPs associated with waist
circumference or insulin resistance in GWAS in relation to
MetS and MetS-score
MetS MetS-score
n 1886 1886
WC
FTO rs1421085 1.02(0.93; 1.12) 0.05(−0.03; 0.14)
MC4Rrs17782313 1 1.16(1.02; 1.32) 0.10(−0.05; 0.24)
IR
PPARG rs1801282 1.04(0.91; 1.19) 0.10(−0.02; 023)
IRS1 rs2943634 0.88(0.79; 0.97) −0.14(−0.23;-0.06)
GCKR rs780094 0.99(0.89; 1.09) 0.05(−0.04; 0.13)
IGF1 rs35767 1.03(0.91; 1.16) 0.03(−0.08; 0.14)
GCK rs1799884 1.07(0.95; 1.20) 0.08(−0.03; 0.22)
Data are presented as PR per minor allele for MetS and as minor allele change
for MetS Score; Mets Metabolic syndrome, WC waist circumference, IR insulin
resistance.
All analyses are adjusted for age, sex and cohort.
1Data available in 853 women.In this study we have explored the biomarkers
involved in MetS development, by studying SNPs related
to these biomarkers. Advantage of this approach is that
according to the principles of Mendelian randomization
the associations we investigated are neither affected by
reverse causality nor by socioeconomic and behavioural
confounders [44]. Furthermore, as all participants were
Caucasian, it is unlikely that our study results have been
affected by population stratification. However, for some
SNPs we measured, like IRS1 rs2943634 [45], allele fre-
quencies are very heterogeneous among different popu-
lations. Therefore, our results warrant replication in
other study populations. Sixteen SNPs which were asso-
ciated in GWAS with MetS related traits were not on
the IBC CVD array. Inclusion of the three waist circum-
ference SNPs, which were not on the array, would prob-
ably have increased the possibility to find associations
with several MetS features. As the global test of inflam-
mation SNPs on hsCRP was already highly significant
(P=7.3*10-6), inclusion of additional SNPs, which were
absent on the IBC CVD array, would not have changed
our results for the global test, but may have revealed
additional individual SNPs. The total number of lipid
SNPs in our study was relatively large and relatively few
lipid SNPs were missing. Therefore we believe that in-
clusion of additional lipid SNPs would not have changed
our results considerably on the group level. The IBC
CVD array covered all insulin resistance SNPs discov-
ered in GWAS. However, up till now for only three
SNPs a genome wide association with HOMA-IR has
been found and replicated. To increase power we also
included those SNPs associated with glucose related
traits in GWAS, which were also associated with
HOMA-IR (P≤0.05). However, as the association
between the group of insulin resistance SNPs and
HbA1C was just significant, the power to detect associa-
tions with MetS and its features was still low.
In conclusion, we found that SNPs associated with
waist circumference or insulin resistance in GWAS were
Povel et al. Cardiovascular Diabetology 2012, 11:133 Page 8 of 9
http://www.cardiab.com/content/11/1/133also associated with MetS. These results are in line with
the hypotheses that weight regulation and insulin metab-
olism are causative factors for MetS.
Individual SNPs for which we found an association
with MetS were MC4R rs17782312 which is involved in
weight regulation and IRS1 rs2943634 which is involved
in insulin resistance.
Appendix I
Loci related to waist circumference, insulin resistance,
inflammatory biomarkers, triglycerides and HDL choles-
terol in genome wide association studies till 01-01-2011
which are not on the IBC CVD array.
Waist circumference
NRXN3 – rs10146997 [46]
TFAP2B – rs987237 [16]
MSRA – rs7826222 [16]
Insulin resistance
Inflammatory biomarkers
HNF1A – rs1183910 [20]
ARL15 – rs4311394 [18]
APOE, APOC1, APOCII – rs4420638 [47]
CDH13 – rs3865188 [48]
Triglycerides
LPL – rs326 [49]
APOA1 – rs2075292 [49]
APOA1, APOC3, APOA4, APOA5 – rs10892151 [50]
APOA1, APOC3, APOA4, APOA5 – rs4938303[21]
CLIP2 – rs7557067 [26]
HDL cholesterol
CETP – rs9989419 [21]
LIPC – rs10468017 [26]
CLIP2 – rs2304130 [21]
MAB,MVK – rs9943753 [21]
Abbreviations
CVD: Cardiovascular diseases; GWAS: Genome-wide association study;
HbA1C: Haemoglobin A1c; HDL: High-density lipoprotein; HWE: Hardy-
weinberg equilibrium; HOMA-IR: Homeostasis model assessment insulin
resistance; hsCRP: High sensitive C-reactive protein; MetS: Metabolic
syndrome; SNP: Single nucleotide polymorphism; T2D: Type 2 diabetes.
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